61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Pacific Biosciences of California Inc
Closed
Sector Healthcare
1.64 3.14
Overview
Share price change
24h
Min
1.59
Max
1.67
Income | 113M -61M |
|---|---|
Sales | 4M 40M |
EPS | -0.22 |
Profit margin | -151.938 |
Recommendations | Buy |
|---|---|
12 Months Forecast | +86.59 upside |
Next Earnings | 13 Feb 2025 |
|---|
Market Cap | 35M 967M |
|---|---|
Previous open | -1.5 |
Previous close | 1.64 |
News Sentiment
By Acuity
50%
50%
161 / 392 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Pacific Biosciences of California Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Pacific Biosciences of California Inc Forecast
Price Target
By TipRanks
86.59% upside
12 Months Forecast
Average 3.06 USD 86.59%
High 6 USD
Low 2 USD
Based on 8 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.
Sentiment
By Acuity
161 / 392 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Pacific Biosciences of California Inc
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company has developed its Single Molecule, Real-Time (SMRT) technology, which enables single molecule, real-time detection of nucleic acid sequences, to address many of the limitations of previous sequencing technologies. The Company’s products include the Sequel II and Sequel IIe instruments and SMRT Cell 8M, which together are capable of sequencing up to approximately eight million deoxyribonucleic acid (DNA) molecules simultaneously, and the previous generation Sequel instrument and Sequel SMRT Cell 1M, which together are capable of sequencing up to one million DNA molecules simultaneously. Its Sequel IIe System increases computational capacity and is designed to enable customers to generate PacBio HiFi reads.
